An increasing body of evidence appears to implicate the lipid bilayer of multidrug resistant (MDR) cells with P-glycoprotein activity. Several cationic amphiphilic drugs (CADs) have been extensively described as modulators of MDR. These same agents are also known to (1) inhibit lysosomal acid sphingomyelinase (ASmase), a phospholipid degrading enzyme, and/or (2) induce phospholipidosis in animal tissues or cultured cell lines. In this report, we randomly selected 17 CADs and evaluated their potency in modulating MDR in the murine MDR P388/ADR leukemia cell line. We compared these results with their ability to inhibit ASmase and observed a significant dose-dependent linear relationship (95% central confidence interval), between ASmase inhibition and MDR reversal. This approach permitted us to identify three new modestly potent chemosensitizers: trimipramine, desipramine, and mianserine. Modulation of MDR was not cell line specific, since CADs at 10 /zM increased doxorubicin (DOX) and vinblastine (VBL) (but not methotrexate, MTX) cytotoxicity in both P388/ADR and the human MDR cell lines MES-SA/Dx5 and K562/R7, but not in the parental drug-sensitive cells. Although all chemosensitizing CADs at 10 /zM significantly increased Rhodamine-123 (Rho-123) accumulation in the human leukemia MDR cell line K562/R7 and most presented significant displacement of the photoaffinity labelling probe iodoarylazidoprazosin, no correlation between these ob,;ervations and the ability of CADs to sensitize MDR cells to DOX and VBL was found. In conclusion, our study strongly suggests that the chemosensitizing potency of agents such as CADs may be due to a dual mechanism of action: direct antagonism of P-gp activity and indirect modulation of P-gp activity through the disruption of cellular lipid metabolism.
I. Introduction
Mammalian cells selected in vitro for resistance to the anthracycline antibiotic doxorubicin (DOX) are typically cross-resistant to a wide variety of hydrophobic cytotoxic agents (multidrug resistance, MDR) (for review see Ref. [1] ). The altered pharmacology of drugs in MDR cells (decreased accumulation and retention) appears to be mediated by the overexpression of the gene product of MDR1, Abbreviations: CADs, cationic amphiphilic drugs; DOX, doxorubicin; VBL, vinblastine; MTX, methot:rexate; DNR, daunorubicin; MDR, multidrug resistance; P-gp, P-glycoprotein; M'IT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium; ASmase, lysosomal acid sphingornyelinase; Rho-123, rhodamine-123a high molecular mass integral membrane protein, P-glycoprotein (P-gp) [2] . The clinical significance of MDR is supported by studies suggesting that the overexpression of the gene encoding for P-gp occurs in patients [3, 4] .
The sequence of P-gp is similar to certain bacterial transport proteins [5] [6] [7] and is ATP-dependent [8] [9] [10] [11] [12] . It appears to act as a relatively nonspecific energy-dependent drug-efflux pump responsible for decreased drug levels in MDR cells. The extraordinarily broad substrate specificity of P-gp has led to speculation as to the identity of the factor(s) which determine how it recognizes its substrate. Recently, Higgins and Gottesman [13] , and Zordan-Nudo et al. [14] proposed that P-gp substrates may initially interact with the lipid bilayer before gaining access to P-gp by partitioning into the lipid phase. Indeed, the implication of lipids in transport processes via transmembrane proteins is a well-established phenomenon (for review see Ref. [15] ), supported recently by several reports which have dearly shown that P-gp-mediated ATP hydrolysis is dependent on the lipid environment [10] [11] [12] . A strong suggestion of a link between lipids and the family of MDR gene products is provided by the observation of Smit et al. that the mouse mdr2 gene, which is 90% homologous to a second human P-gp gene MDR3, codes for a protein which plays an essential role in phospholipid transport [16] . Finally, both Callaghan et al. and Wadkins and Houghton have recently proposed that the interaction of chemosensitizers with cellular lipids is a contributing factor in MDR modulation [17, 18] . Previously, we have described a potent MDR modulator, SR33557, which did not directly interact with P-gp [19] . We also suggested that the mechanism of action of this novel chemosensitizer may be linked to its inhibitory effect on lysosomal acid sphingomyelinase (ASmase). In order to further investigate the role of altered lipid composition in modulating MDR, we randomly selected 17 cationic amphiphilic drugs (CADs), 14 of which have previously been reported to modulate MDR [19] [20] [21] [22] [23] [24] [25] . All have previously been described elsewhere as either having an inhibitory effect on ASmase, or inducing generalized lipidosis (phospholipid storage disorders) in cultured cell lines and/or tissues (for review see Ref. [26] ). We determined the potency of these agents in inhibiting ASmase activity in the murine MDR P388/ADR leukemia cell line, and in modulating resistance to DOX and vinblastine (VBL).
Materials and methods
SR33557 ((2-isopropyl-1-((4-(3-N-methyl-N-(3,4-dimethoxy-fl-phenethyl)amino)propyloxy)benzenesulfonyl))-indolizine) and its derivatives, SR33510 (1-~-hydroxybenzinesulfinyl-2-isopropylindolizine), and SR45813 (N-(3-chloro-l-propyl)-N-methyl-3,4-phenethylamine) were a generous gift from Dr. Pierre Chatelain (Sanofi-Labaz Research Center, Brussels, Belgium) [27] . Perhexiline analogues Pex 2, Pex 5, Pex 7, and Pex 15 were provided by Dr. Decker (Institut de Pharmacologie, UA 589 CNRS, Facult6 de M6decine, Strasbourg, France) [28] . DOX was obtained from Adria Laboratories (Columbus, OH), VBL from Eli Lilly (Indianapolis, IN), and methotrexate from Lederle Parenterals (Carolina, Puerto Rico). CADs and all other agents were purchased from Sigma Chemical Co. (St. Louis, MO). CADs were solubilized in dimethyl sulfoxide or, if insoluble, in sterile distilled water. Dimethyl sulfoxide concentrations in assays never exceeded 0.1% (v/v).
Cell culture
The murine leukemia P388 cell line and the MDR subline P388/ADR were originally obtained from Dr. J.G.
Mayo (Mammalian Genetics and Animal Production
Branch, National Cancer Institute, Bethesda, MD). The cells were maintained in RPMI 1640 medium (M6rieux, Lyon, France) supplemented with 10% heat-inactivated fetal calf serum (Flow Laboratories, McLean, VA), 2 mM glutamine, 20/zM fl-mercaptoethanol, and antibiotics (200 units penicillin/ml, 100 /xg streptomycin/ml). The human sarcoma MES-SA and its MDR variant MES-SA/Dx5 [29] , as well as the erythroleukemia cell line K562 and its MDR subline K562/R7 [30] are permanently maintained in our laboratory. These cells were grown in McCoy's medium (Irvine Scientific, Santa Ana, CA) supplemented as described above. Cells were maintained at 37°C in a humidified atmosphere containing 5% CO 2. Cell stocks were screened routinely for Mycoplasma by the DNA hybridization method (Gen-Probe, San Diego, CA).
MTT cytotoxicity assay
P388 and P388/ADR cells (6.105 cells/500/xl) were incubated in complete medium with and without drugs for 1 h at 37°C in an atmosphere of 5% CO 2. Cells were then washed and resuspended at 2.105 cells/ml, and 0.1-ml aliquots were removed and seeded in 96-well multiplates for a further 48 h drug-flee incubation. MES-SA, MES-SA/Dx5, K562, and K562/R7 cells were directly seeded in 96-well plates (8000 cells/well) and incubated with and without drugs for 72 h at 37°C. Growth inhibition was evaluated by the M'Iq" colorimetric method on triplicate assays as previously described [19, 31] . The absorbance was quantitated with a ThermoMax microplate reader (Molecular Devices, Menlo Park, CA). The ICs0 (drug concentration resulting in 50% inhibition of MT'F dye formation, compared to controls) was determined directly from semilogarithmic dose-response curves.
Determination of acid sphingomyelinase activity
Enzymatic activity was determined as described previously [32] . 5 • 10 6 cells treated with or without CADs for 1 h at 37°C were washed with 0.9% NaC1 and the cell pellets were resuspended in distilled water and sonicated. Protein concentrations were determined by the procedure of Hartree [33] . Briefly, a fluorescent pyrenesulfonylamidoundecanoyl sphingomyelin substrate was added to sonicated suspension in the presence of Triton X-100 for 2 h at 37°C. The reaction was stopped by the addition of 1.5 ml heptane and 0.45 ml isopropyl alcohol, followed by 0.25 ml water, and centrifugation at 1000 × g for 10 min. The product of the enzyme reaction, ceramide (which is linked to the fluorescent moiety), was determined fluorometrically by analyzing the upper heptane-rich phase at 351 and 378 nm (excitation and emission wavelengths, respectively). This product was quantitated by measuring the fluorescence intensity of known quantities of fluorescent ceramide (standard curve). The sphingomyelinase activity in treated cells is expressed as nmoles of ceramide/h/mg protein and is compared to that of untreated cells.
Alternatively, ASmase activity was determined (with similar results) by using t]he natural [14C]choline-labelled substrate, under previously reported conditions [34] .
Flow cytometric assays
Accumulation of Rhodamine-123 (Rh-123) was carried out essentially as previously described [35] . K562 and K562/R7 cells were passed through a nylon filter, centrifuged, and suspended in modified Hank's balanced salt solution (HBSS) containing 10 mM Hepes and 5% calf serum. Aliquots of 1 ml containing 2.5-105 cells were incubated with or without CADs at 37°C for 1 h. Rh-123 was added to give a final concentration of 0.1 /zg/ml, followed by 45 min incubation at 37°C. Cells were centrifuged and the pellet resuspended in 200 /zl of ice-cold HBSS. Accumulation of Rh-123 was determined with a fluorescence activated cell sorter (FACStar, Becton-Dickinson Corp., Mountain View, CA).
Photoaffinity labelling studies
Displacement of the P-I~ probe iodoaryl azidoprazosin was performed essentially as previously described [36, 37] . K562 and K562/R7 cells (100/zg protein) were incubated with [125I]iodoaryl azidoprazosin (81.4 TBq/mmol, NENDupont, Boston, MA) with and without CADs in a 10 mM Tris-HC1 buffer (pH 7.4) at a final volume of 50/xl. These preparations were incubated at 25°C for 1 h in the dark, followed by a 20 min exposure to a 366 nm UV source (UVP, San Gabriel, CA). 50 /zl of loading buffer was added and proteins separated on a 6% polyacrylamide-SDS gel. Immunodetection using the anti-P-gp monoclonal antibody C219 [38] (Centocor, Malvern, PA) was performed using the light-enhanced chemiluminescence Western Blot protocol (Amersham Corp., Arlington Heights, IL), followed by autoradiography and densitometry. ferent CADs presented distinct dose-effect curves. The most potent DOX modulators were perhexiline, SR33557, and quinacrine. These CADs were also effective at modulating VBL resistance in P388/ADR cells (Table 1) , but had no effect on the non-MDR related drug methotrexate (MTX) (data not shown). None of the CADs had any significant impact on the parental drug-sensitive cell line P388 (data not shown).
Statistical analysis 3.2. Inhibition of lysosomal acid sphingomyelinase activity
Statistical calculations were performed using StatView software (Abacus Concepts, Berkeley, CA). Significance and confidence limits were estimated as described by Dowdy and Wearden [39] .
Results

Modulation of DOX and VBL resistance
The dose-dependent effect of 17 CADs on DOX and VBL resistance was tested for in P388/ADR cells. A wide diversity in DOX modulating potency was observed with no overridding dose-effect profile (Table 1) . Indeed, difParallel to the DOX and VBL resistance modulation assay, the same series of CADs were tested for their ability to inhibit ASmase activity in P388/ADR cells. The compounds were tested at concentrations ranging from 0.1 to 100 /xM. All CADs that modulated DOX and VBL resistance presented significant dose-effects within the micromolar range. Table 2 shows most of the results of these experiments. Except for chloroquine, inhibition of ASmase activity was dose-dependent within the micromolar range. However, as in the resistance modulation assays these CADs did not present similar dose-effect profiles. For example, certain agents such as tamoxifen and trimipramine shouldered-off at about the 3 /xM concentration while CADs such as perhexiline presented a linear dose-re- sponse from 1 to 10 /xM. Quinacrine, on the other hand, had a biphasic effect. The most potent ASmase inhibitors were perhexiline, SR33557 (at 20-30 /zM, see Ref. [19] ), quinacrine, and tamoxifen. Inhibition of ASmase by CADs was only observed on treated intact cells, and not on cell sonicates.
Correlation between inhibition of ASmase activity and modulation of MDR
Since it clearly appeared that inhibitors of ASmase could also modulate MDR within the same concentration range, we directly compared both effects. Fig. 1 compares the ASmase inhibition activity of these CADs at 10 /~M against their DOX chemosensitizing potency. These data demonstrated good correlation (r= 0.80, r 2 = 0.64) between these two activities. When residuals were plotted against the independent variable (ASmase inhibition), very little differences in variance were seen (Fig. 1, inset) . This relationship was estimated to be linear at the 0.05 level of significance. Furthermore, the equation of the straight line model (y--0.13 × (+0.17)-0.21) can be used for prediction with a 95% central confidence interval as estimated by the one-tailed t-test at a = 0.05. Fig. 2 Table 1 as described in Section 2. The impact of these agents at 10 /~M on both reversal of DOX resistance and inhibition of ASmase activity as listed in Tables 1 and 2 dose-dependent ASmase inhibition of CADs against their DOX chemosensitizing potency. Again, the relationship was estimated to fit a straight line model with good correlation (r = 0.70, r 2 -0.49), and the line's equation (y = 0.09 × (+0.11)+ 0.65) can be used for prediction with a 95% central confidence interval. In this case, the plotted residuals show slightly greater variance as the x-axis (ASmase inhibition) increases, but remain within an acceptable range (Fig. 2, inset) . In these comparative analysis SR33557 at 10 /zM was omitted, as this very Table 1 as described in Section 2. The impact of these agents at 1, 3, 6, and 10/zM on both reversal of DOX resistance and inhibition of ASmase activity as listed in Tables 1 and 2 were plotted against each other. A linear relationship was estimated with the following definitions: y = 0.09× (+0.11)+0.65, r = 0.70, r 2 = 0.49, t Statistic = 7.39 (P < 0.001), and F-ratio = 54.64 (P < 0.001). Tables 1 and 2 were plotted against each other. A linear relationship was estimated with the following definitions: y = 0.03 × (+0.08)+ 1.12, r = 0.78, r 2 = 0.61, t Statistic = 4.92 (P < 0.001), and F-ratio = 24.22 (P < 0.001).
powerful chemosensitizer most likely entails other mechanisms of action at this cortcentration [40] .
In an effort to determine if such correlations could also be found with another MDR-related drug, we compared the ASmase inhibition of CADs with their ability to modulate VBL resistance in the P388/ADR cell line. Fig. 3 shows that there indeed exists such a correlation. The straight line model having the equation y = 0.03 × (+0.08) + 1.12 (r = 0.78, r 2 = 0.61). Finally, structural analogues of SR33557 (SR33510 and SR45813), of perhexiline (Pex 7 and Pex 15), and 0.1% dimethyl sulfoxide had no effect either on ASmase or MDR reversal (data not shown).
Characterization of three new chemosensitizers
In order to determine if the three CADs which have never been previously de,;cribed as chemosensitizers (desipramine, mianserine, and trimipramine) are truly modulators of MDR, we tested these agents on two other MDR cell lines, MES-SA/Dx5 and K562/R7. As shown in Table 3 , all three CADs presented modest chemosensitizing activity for DNR and VBL on the MDR cell lines, whereas they did not have any effect on the parental drug-sensitive cell line MES-SA and K562 (data not shown). Furthermore, these CADs had no effect on MTX cytotoxicity on these cell lines.
Flow cytometry analysis of rhodamine-123 accumulation
In order to confirm that CADs inhibited the activity of P-gp, we evaluated their impact on Rho-123 accumulation in the MDR cell line K562/R7. As shown in Table 4 , all CADs at 10 /xM significantly increased Rho-123 accumulation in K562/R7 cell line, whereas they had no such effect on the parental drug-sensitive K562 cell line. Structural analogues of SR33557 (SR33510 and SR45813), of perhexiline (Pex 7 and Pex 15), and 0.1% dimethyl sulfoxide had no effect on Rho-123 accumulation (data not shown).
Photoaffinity labelling studies
In an attempt to further characterize the mechanism of action of CADs, we performed photoaffinity labelling studies on the K562/R7 cell line using the P-gp probe [125I]iodoaryl azidoprazosin. Although a number of CADs significantly displaced the radiolabelled P-gp probe (10% to 40%) at 10 gM (Table 5) , no correlation was observed between their ability to displace azidoprazosin binding and their chemosensitizing potency. Furthermore, two of the most potent chemosensitizers SR33557 and quinacrine, along with desipramine and clomipramine, presented less than a 10% inhibition of photolabelling. 10 /xM vinblastine, used as a positive control, displaced 67% of azidoprazosin binding. a Concentration of anticancer dntg that inhibited cell growth by 50% in 72 h. Values are means of at least three independent experiments (S.D. < 10%). b Values in parentheses represenl fold reversal which is the ICso for anticancer drug alone divided by theICso for drug in the presence of chemosensitizer.
Discussion
MDR cells are characterized by impaired drug accumulation associated with an increased expression of P-gp that is believed to be an energy-dependent drug-effiux pump [1] . However, as recently pointed out, the paradox is substrate specificity [13] . Not only does P-gp recognize, with moderate to low affinity, a diverse group of anticancer drugs, but there is an equally impressive variety of structurally diverse agents which modulate MDR [41] . Presently, the precise mechanisms involved in P-gp specificity remain speculative but the cationic amphiphilic nature of most of these drugs suggests that a strong interaction can and will occur with certain polar lipids resulting in complexes formed by hydrophobic and electrostatic forces [42] . These drugs are most often CADs and contain a hydrophobic domain and an ionizable nitrogen (which can become protonated) [26, 43, 44] .
Higgins and Gottesman have suggested that P-gp may interact with drugs which are intercalated within the lipid bilayer; they also proposed that differences in membrane lipid composition could affect drug partitioning and therefore explain the variable resistance patterns seen for P-gp in different tumor cell lines [13] . Indeed, the participation of the lipid phase in P-gp activity has recently been strengthened by the observation that substrate stimulation of P-gp-mediated ATP hydrolysis was found only when the protein was reconstituted within a phospholipid vesicle [10] [11] [12] . Further evidence for the role of the lipid bilayer Rho-123 accumulation was measured as described in Section 2. b Values are means of at least three independent experiments ___ S.E. c p values were calculated using the paired one-tailed Student's t-test. [18] . The implication of the lipid phase in P-gp activity may shed some light on the mechanisms of action of chemosensitizers. Several CADs have previously been described as inhibiting ASmase activity on various cultured cell lines [43] [44] [45] [46] [47] . Such inhibitors of ASmase generally cause the accumulation of its substrate, sphingomyelin, within the cells leading to lipidosis and often aberrant constitutional and morphological alterations in membranes [19, 43] . In other studies, these same CADs, used at similar concentrations, have also been described as modulating MDR; these include perhexiline, chlorpromazine, trifluoperazine, prochlorperazine, imipramine, clomipramine, quinacrine, and dibucaine [20] [21] [22] [23] [24] [25] . Such observations raise the possibility of a link between inhibition of P-gp activity and either phospholipidosis and/or ASmase inhibition.
In an effort to test the above-mentioned hypothesis, we randomly selected a number of CADs that have previously been described elsewhere as either having an inhibitory effect on ASmase, or inducing generalized lipidosis. Our present report demonstrates a strong correlation between the degree of inhibition of ASmase and modulation of MDR, whereas no correlation was observed between the capacity of these CADs to inhibit azidoprazosine photolabelling of P-gp and their ability to reverse the MDR phenotype. Moreover, the apparent link between inhibition of ASmase and modulation of MDR has permitted us to serendipitously discover three new modestly active chemosensitizers, trimipr~tmine, desipramine and mianserinc.
From the observations presented in this study it appears that CADs affect both the' activity of a lysosomal enzyme and the activity of a plasma membrane protein. We suggest that modulation of MDR by CADs may be the additive consequence of a direct inhibition of P-gp activity (i.e., drug binding) and an indirect mechanism based on the disruption of the lipid environment as indicated by the inhibition of ASmase and the ensuing phospholipidosis. We propose that the modification of lipid trafficking could interfere with the activity of P-gp, perhaps by affecting the ATP binding region or the drug-binding region. Spector and Burns [48] have previously suggested that changes in membrane lipid composition may perturb the function of integral proteins that span the lipid bilayer. It is also possible that the modified lipid constitution decreases the interaction between DOX and VBL with the plasma membrane. This would then lead to a decreased capture of drug within the lipid bilayer and a greater quantity gaining access to the intracellular targets. Similar hypotheses were recently proposed by Thierry et al. when they observed that empty liposomes inhibited [3H]vincristine binding to P-gp [44] .
Of course, it is impossible at this point to rule out other mechanisms implicated in chemosensitization. Indeed, CADs could also modulate MDR, perhaps by direct interaction with the plasma membrane [13] or by mimicking sphingoid bases and inte.rfering with signal transduction pathways and/or protein kinase C [26, 49] , and also perhaps by disrupting intracellular drug trafficking [40] . However, the assay for ASmase activity would still remain a useful tool for quantitative evaluation of the potency of a drug to induce lipidosis and indirectly modulate the MDR phenotype. It is important to note that the effects of these CADs on lipid composition did not increase the cytotoxicity of non-MDR drugs such as methotrexate, nor did they affect the cytotoxicity of DOX and VBL in the parental drug-sensitive cell lines, 'which do not express P-gp, even though ASmase was quite similarly inhibited (data not shown).
The lack of correlation between inhibition of azidopine P-gp photoaffinity labelling and modulation of MDR by certain compounds has previously been described [12, 50, 51] . It is of course possible for P-gp to have more than one drug binding :site, and also, as suggested by Zordan-Nudo et al., differences in displacing P-gp probes may be related to the ability of certain chemosensitizers to serve as substrates for P-gp efflux [14] . Indeed, P-gp substrates such as verapamil are less potent in inhibiting P-gp photoaffinity labelling by azidopine, as compared to Triton X-100 which is not effluxed from MDR cells [14] .
Although it appears that all ASmase inhibitors will modulate MDR within a predictive range, all modulators of MDR do not inhibit ASmase. For example, verapamil and cyclosporin A, both potent MDR modulators, have no effect on ASmase activity (data not shown). However, both of these drugs have been described as having the ability of interfering with membrane biochemistry. Verapamil, for example, was shown by Ramu et al. to alter the lipid metabolism in P388/ADR cells by increasing the synthesis of phosphatidylcholine [52] and by Retzinger and Cohen to be specifically sequestered in and disrupting plasma membranes [53] . Finally, Niebylski and Petty have shown that cyclosporin A partitions into cellular membranes which may then undergo structural modifications [54] .
In conclusion, the concept that modifying the cellular lipid constitution by pharmacological agents can lead to the reversal of MDR may provide a new avenue of exploration for future research in screening and/or designing of potent chemosensitizers [55] .
